Eversept Partners, LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Eversept Partners, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Nov 08, 2023	SELL	$5.4 - $13.37 $111,780 - $276,759	-20,700 Reduced 29.7%	49,008 $470,000
Q2 2020 Aug 13, 2020	SELL	$5.4 - $13.37 $111,780 - $276,759	-20,700 Reduced 29.7%	49,008 $470,000
Q1 2019 Nov 08, 2023	BUY	$10.31 - $14.38 $718,689 - $1 Million	69,708 New	69,708 $974,000
Q1 2019 May 14, 2019	BUY	$10.31 - $14.38 $708,173 - $987,733	68,688 Added 6734.12%	69,708 $975,000
Q4 2018 Feb 13, 2019	BUY	$8.63 - $12.4 $8,802 - $12,648	1,020 New	1,020 $10,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.